These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29796823)

  • 1. Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis.
    Katsuno T; Ozaki T; Ozeki T; Hachiya A; Kim H; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Mizuno M; Ito Y; Maruyama S
    Clin Exp Nephrol; 2018 Dec; 22(6):1341-1350. PubMed ID: 29796823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Drug Monitoring of Mycophenolic Acid in Lupus Nephritis: A Review of Current Literature.
    Łuszczyńska P; Pawiński T
    Ther Drug Monit; 2015 Dec; 37(6):711-7. PubMed ID: 26034895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
    Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
    J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
    Jesus D; Rodrigues M; da Silva JAP; Inês L
    Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis.
    Kittanamongkolchai W; Rukrung C; Supasiri T; Lertjirachai I; Somparn P; Chariyavilaskul P; Avihingsanon Y
    Lupus; 2013 Jun; 22(7):727-32. PubMed ID: 23651860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Class IV Lupus Nephritis with Mycophenolate Mofetil Monotherapy.
    Nawata T; Kubo M; Fujii S; Shiragami K; Ikegami T; Kobayashi S; Hisano S; Yano M
    Intern Med; 2018 Jul; 57(14):2067-2070. PubMed ID: 29491296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
    Gul H; Mushtaq MS; Salim B; Samreen S; Nasim A; Khan M
    J Ayub Med Coll Abbottabad; 2020; 32(4):454-458. PubMed ID: 33225643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
    Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
    Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan.
    Yasuda S; Atsumi T; Shimamura S; Ono K; Hiromura K; Sada K; Mori M; Takei S; Kawaguchi Y; Tamura N; Takasaki Y
    Mod Rheumatol; 2015; 25(6):854-7. PubMed ID: 25800636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
    Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience.
    Mendonca S; Gupta D; Ali S; Gupta P
    Saudi J Kidney Dis Transpl; 2017; 28(5):1069-1077. PubMed ID: 28937065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
    Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
    Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study.
    Park DJ; Kang JH; Lee KE; Bae SC; Chung WT; Choe JY; Jung SY; Kim YS; Lee HS; Lee J; Lee YA; Park SH; Park YJ; Suh CH; Yoo DH; Lee SS
    Clin Exp Rheumatol; 2019; 37(1):89-96. PubMed ID: 29998829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
    Choi CB; Won S; Bae SC
    Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness and safety of mycophenolate mofetil in lupus nephritis.
    Elyan M; Ballou S
    Clin Rheumatol; 2009 Jul; 28(7):835-40. PubMed ID: 19319623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
    Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients.
    Hui-Yuen JS; Tran T; Taylor J; Truong K; Li X; Bermudez LM; Starr AJ; Eichenfield AH; Imundo LF; Askanase AD
    J Clin Rheumatol; 2016 Mar; 22(2):75-9. PubMed ID: 26906299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.
    Kawazoe M; Kaneko K; Yamada Z; Masuoka S; Mizutani S; Yamada S; Shikano K; Sato H; Kaburaki M; Muraoka S; Kawai S; Nanki T
    Clin Rheumatol; 2019 Jun; 38(6):1571-1578. PubMed ID: 30778862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
    Wang J; Hu W; Xie H; Zhang H; Chen H; Zeng C; Liu Z; Li L
    Lupus; 2007; 16(9):707-12. PubMed ID: 17728363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.